LL-37 Dosage Guide

Evidence-based protocols for the only human cathelicidin antimicrobial peptide — immune defense, wound healing, biofilm disruption, vitamin D synergy, stacking, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

LL-37

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is LL-37?

LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide derived from the C-terminal domain of the human cathelicidin protein hCAP18. It is an endogenous host defense peptide, meaning your body naturally produces it as a critical component of the innate immune system. LL-37 is expressed by neutrophils, macrophages, epithelial cells, mast cells, and other immune cells throughout the body.

What makes LL-37 remarkable is its multi-functional nature. It is not simply an antimicrobial agent — it is a master regulator of innate immunity. LL-37 provides direct antimicrobial activity by disrupting bacterial, viral, and fungal membranes. It recruits immune cells to sites of infection through chemotactic signaling. It modulates Toll-like receptor (TLR) signaling to fine-tune the inflammatory response. It promotes wound healing through angiogenesis and re-epithelialization. And it disrupts bacterial biofilms — structured microbial communities that are notoriously resistant to antibiotics.

A key insight is that vitamin D is one of the primary regulators of LL-37 expression. When vitamin D binds to its receptor (VDR) in immune cells, it directly upregulates transcription of the gene encoding hCAP18. This is one of the major mechanisms by which vitamin D supports immune function — and why vitamin D deficiency is associated with increased infection susceptibility. Exogenous LL-37 administration aims to supplement or boost levels beyond what the body naturally produces, particularly in individuals with suboptimal vitamin D status or compromised immune function.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from preclinical studies and community protocols — not from approved pharmaceutical labeling.

Key Characteristics:

Only human cathelicidin — LL-37 is the sole cathelicidin antimicrobial peptide in humans, derived from the precursor protein hCAP18
37 amino acids — begins with two leucine residues (LL) and is 37 residues long, hence the name LL-37
Broad-spectrum antimicrobial — disrupts membranes of gram-positive and gram-negative bacteria, enveloped viruses, and fungi through direct physical interaction
Immunomodulatory — recruits immune cells (chemotaxis), modulates TLR signaling, promotes macrophage phagocytosis, enhances neutrophil function
Anti-biofilm activity — penetrates and disrupts bacterial biofilm structures, making protected bacteria vulnerable to immune clearance
Wound healing — promotes angiogenesis (new blood vessel formation) and re-epithelialization at wound sites
Vitamin D regulated — endogenous LL-37 expression is upregulated by vitamin D through VDR-mediated gene transcription
Short plasma half-life — minutes to hours in circulation, but immune modulation effects persist beyond the plasma half-life

For a complete overview of its mechanism and research, see our full LL-37 profile. New to peptides? Start with the Beginner's Guide to Peptides.

How LL-37 Dosage Is Determined

LL-37 dosing is less standardized than many other research peptides because the majority of the research base is preclinical (in vitro and animal models). There are no large-scale, dose-finding clinical trials for exogenous LL-37 administration in humans. Current dosing protocols are derived from three sources: the concentrations used in preclinical studies, the known physiological concentrations of endogenous LL-37 in human tissues, and community experience from practitioners and users.

Endogenous LL-37 Levels

In healthy individuals, LL-37 is present at concentrations of approximately 1–5 mcg/mL in plasma, with higher local concentrations at sites of infection or inflammation. During active infection, local LL-37 levels can increase dramatically as neutrophils and epithelial cells upregulate production. The goal of exogenous administration is to supplement these levels — particularly in individuals with suboptimal endogenous production due to vitamin D deficiency, compromised immune function, or chronic infection.

Preclinical Antimicrobial Data

In vitro studies demonstrate that LL-37 exhibits antimicrobial activity at concentrations in the low micromolar range. Its minimum inhibitory concentration (MIC) varies by pathogen but typically falls between 1–32 mcg/mL depending on the organism. Anti-biofilm effects have been observed at sub-MIC concentrations, suggesting that even modest increases in LL-37 levels may provide meaningful biofilm disruption.

Immunomodulatory Research

The immunomodulatory effects of LL-37 — chemotaxis, TLR modulation, macrophage activation — occur at concentrations that overlap with the antimicrobial range. Research by Bowdish, Davidson, and others has demonstrated that LL-37 modulates cytokine production, enhances phagocytosis, and recruits immune cells at physiologically relevant concentrations. These effects do not require supraphysiological doses, supporting the use of conservative dosing protocols.

Community-Derived Protocols

Practitioner experience has converged on subcutaneous dosing in the 50–200 mcg per day range. This range is based on achieving meaningful systemic immune support while minimizing the risk of excessive immune activation. Lower doses (50 mcg/day) are used for maintenance and prevention, while higher doses (100–200 mcg/day) are reserved for acute infections and active immune challenges.

Strength of evidence: Strong preclinical, limited clinical. LL-37 has extensive basic science and preclinical research supporting its antimicrobial, immunomodulatory, and wound healing properties. However, human clinical trials for exogenous LL-37 administration are extremely limited. Dosing protocols are derived from preclinical data extrapolation and community experience, not from controlled human dose-finding studies.

Standard LL-37 Dosage Ranges

LL-37 is most commonly administered by subcutaneous injection for systemic immune support. Topical and intranasal routes are also used for localized applications. The following ranges represent community-consensus dosing based on practitioner experience and preclinical data extrapolation.

Subcutaneous Injection — Dosage by Protocol

Protocol	Dose per Injection	Frequency	Duration	Notes
Immune Maintenance	50 mcg	Once daily or every other day	4–8 weeks	Low-dose baseline immune support; lowest risk of adverse effects
Standard Immune Support	100 mcg	Once daily	2–4 weeks	Most common protocol; balances efficacy with safety
Acute Infection Protocol	100–200 mcg	Once daily	2–4 weeks	For active infections; higher dose for increased antimicrobial and immune activity
Biofilm Disruption	100–200 mcg	Once daily	3–6 weeks	Longer duration for chronic biofilm-associated conditions; often combined with conventional antimicrobials

Injection Timing

No strict fasting requirement: Unlike GHRPs, LL-37's mechanism does not depend on GH release, so fasting is not required before injection
Consistency matters: Inject at the same time each day for consistent serum levels
Morning administration preferred: Many practitioners recommend morning injection to support immune activity during the day when pathogen exposure is highest
Rotate injection sites: Abdomen, thigh, and upper arm are standard subcutaneous sites; rotate to avoid localized reactions

Start low, titrate up. LL-37 is a potent immune activator. Starting at 200 mcg without prior experience can cause flu-like symptoms, fatigue, and pronounced injection site reactions as the immune system ramps up. Begin at 50 mcg daily for 3–5 days, then increase to 100 mcg. Only escalate to 200 mcg if well-tolerated and clinically indicated.

Administration Routes

One of LL-37's distinguishing features is the variety of administration routes available. The optimal route depends on the clinical target — systemic immune support, wound healing, or upper respiratory defense each benefit from a different approach.

Route	Typical Dose	Best For	Notes
Subcutaneous Injection	50–200 mcg daily	Systemic immune support, antimicrobial defense, biofilm disruption	Most standardized route; best for general immune enhancement and chronic conditions
Topical Application	Varies by formulation	Wound healing, skin infections, localized tissue repair	Applied directly to the wound or infection site; dosing depends on wound size and formulation concentration
Intranasal	25–50 mcg per nostril	Upper respiratory infections, sinus support	Delivers LL-37 directly to nasal and sinus mucosa; less standardized than SubQ

Subcutaneous Injection (Primary Route)

Subcutaneous injection is the most common and best-standardized route for LL-37. It provides systemic distribution and is the method used in the majority of community protocols. Standard injection sites include the abdominal area (avoiding the navel), anterior thigh, and upper arm. Use an insulin syringe (29–31 gauge) for minimal discomfort.

Topical Application (Wound Healing)

For wound healing and localized skin infections, LL-37 can be applied topically. This route delivers the peptide directly to the tissue where it promotes angiogenesis, re-epithelialization, and local antimicrobial defense. Topical formulations vary — some practitioners reconstitute LL-37 and apply it directly to the wound, while others use compounding pharmacies to prepare topical creams or gels at specified concentrations.

Intranasal Administration (Respiratory Support)

Intranasal LL-37 targets the nasal and sinus mucosa directly, making it a logical choice for upper respiratory infections and chronic sinus conditions. The nasal epithelium naturally expresses LL-37, so intranasal supplementation augments an existing defense mechanism. Typical protocols use 25–50 mcg per nostril, 1–2 times daily during acute upper respiratory challenges.

Route selection matters. Match the administration route to your goal. Subcutaneous injection for systemic immune support. Topical for wound healing. Intranasal for upper respiratory defense. Using subcutaneous injection for a surface wound, or topical application for systemic immune support, is not optimal.

Calculate Your LL-37 Dose

LL-37 is supplied as a lyophilized (freeze-dried) powder, typically in 2 mg or 5 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 5 mg (5,000 mcg) of LL-37
Bacteriostatic water added: 2 mL
Concentration: 5,000 mcg ÷ 2 mL = 2,500 mcg per mL
Target dose: 100 mcg
Volume to draw: 100 ÷ 2,500 = 0.04 mL = 4 units on an insulin syringe

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	50 mcg Dose	100 mcg Dose	200 mcg Dose
1 mL	5,000 mcg/mL	1 unit (0.01 mL)	2 units (0.02 mL)	4 units (0.04 mL)
2 mL	2,500 mcg/mL	2 units (0.02 mL)	4 units (0.04 mL)	8 units (0.08 mL)
2.5 mL	2,000 mcg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.1 mL)
5 mL	1,000 mcg/mL	5 units (0.05 mL)	10 units (0.1 mL)	20 units (0.2 mL)

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

LL-37 Dosage by Goal

LL-37's multi-functional nature — antimicrobial, immunomodulatory, wound healing, anti-biofilm — makes it applicable to a wide range of goals. The optimal protocol varies depending on whether you are targeting general immune maintenance, acute infection, biofilm disruption, wound healing, or gut health.

General Immune Maintenance

For individuals seeking to augment baseline innate immune function — particularly those with suboptimal vitamin D status, frequent infections, or compromised immune capacity. This is the lowest-risk, most conservative protocol.

Dose: 50 mcg SubQ daily or every other day
Duration: 4–8 weeks, then 2–4 weeks off
Stack: Optimize vitamin D (40–60 ng/mL) to support endogenous LL-37 production
Note: This protocol supports immune readiness without significant immune stimulation

Acute Infection Support

For active bacterial, viral, or fungal infections. Higher doses provide greater direct antimicrobial activity and stronger immune cell recruitment. This is a time-limited protocol — use for the duration of the acute infection and then taper or discontinue.

Dose: 100–200 mcg SubQ daily
Duration: 2–4 weeks (for the duration of the acute challenge)
Stack: + Thymosin Alpha-1 1.6 mg SubQ 2–3x per week for innate + adaptive immune synergy
Note: LL-37 complements but does not replace conventional antimicrobial treatment for diagnosed infections

Biofilm Disruption (Lyme Disease Community Interest)

LL-37's anti-biofilm properties have generated significant interest in the Lyme disease community, where Borrelia burgdorferi forms biofilm structures that resist antibiotic penetration. LL-37 can disrupt these biofilm matrices, making the bacteria within them vulnerable to antimicrobial clearance. This protocol uses longer durations and is typically combined with conventional antimicrobials under medical supervision.

Dose: 100–200 mcg SubQ daily
Duration: 3–6 weeks (longer than acute protocols due to biofilm penetration time)
Stack: Often combined with conventional antimicrobials prescribed by a Lyme-literate physician; + Thymosin Alpha-1 for adaptive immune support
Note: Biofilm disruption may cause a Herxheimer-like reaction (die-off symptoms) as protected bacteria are exposed to immune clearance. Start at 50 mcg and titrate slowly.

Herxheimer reactions: When LL-37 disrupts biofilms, bacteria that were previously shielded become exposed to the immune system and antimicrobials. This can cause a temporary worsening of symptoms — often called a “Herxheimer reaction” or “die-off.” Symptoms may include fatigue, muscle aches, headache, and flu-like feelings. If this occurs, reduce the dose temporarily rather than stopping abruptly, and consult your healthcare provider.

Wound Healing & Tissue Repair

LL-37 promotes wound healing through multiple mechanisms: angiogenesis (new blood vessel formation), re-epithelialization, fibroblast migration, and local antimicrobial defense at the wound site. For wound healing, topical application is preferred to deliver LL-37 directly to the tissue, though subcutaneous injection can complement topical use for systemic support.

Primary route: Topical application directly to the wound
Complementary: + SubQ 50–100 mcg daily for systemic support
Duration: Until wound closure or significant improvement
Stack: + BPC-157 250 mcg SubQ near the injury site for complementary wound healing through growth factor upregulation

Upper Respiratory & Sinus Support

For upper respiratory infections, chronic sinusitis, or seasonal respiratory challenges. Intranasal administration delivers LL-37 directly to the nasal and sinus mucosa where it augments the mucosal antimicrobial defense barrier.

Primary route: Intranasal, 25–50 mcg per nostril, 1–2x daily
Complementary: + SubQ 50–100 mcg daily for systemic immune support
Duration: 1–3 weeks (for acute episodes); can be used seasonally
Note: Intranasal dosing is less standardized than subcutaneous; start conservatively

Gut Health & Intestinal Barrier Support

LL-37 is naturally expressed in the gastrointestinal tract where it contributes to mucosal defense and intestinal barrier integrity. Exogenous LL-37 may support gut health by providing antimicrobial defense against gut pathogens, modulating intestinal inflammation, and supporting mucosal barrier function.

Dose: 50–100 mcg SubQ daily
Duration: 4–8 weeks
Stack: + BPC-157 250 mcg SubQ or oral for direct gut healing support; + KPV for anti-inflammatory synergy in the gut
Note: LL-37 complements gut-specific peptides like BPC-157 through different mechanisms (antimicrobial + barrier support vs. growth factor upregulation)

Match the protocol to the goal. LL-37's versatility is a strength, but it also means there is no single “best” protocol. Define your primary goal first, select the appropriate route and dose, and titrate based on response. Most users benefit from starting with the standard immune support protocol (100 mcg SubQ daily for 2–4 weeks) before moving to specialized protocols.

The Vitamin D – LL-37 Connection

The relationship between vitamin D and LL-37 is one of the most well-established connections in innate immunology. Understanding this relationship is critical for anyone using or considering exogenous LL-37, because vitamin D status directly determines how much LL-37 your body produces endogenously.

How Vitamin D Regulates LL-37

When vitamin D (as its active form 1,25-dihydroxyvitamin D3) binds to the vitamin D receptor (VDR) in immune cells — particularly monocytes, macrophages, and epithelial cells — it directly upregulates transcription of the CAMP gene. The CAMP gene encodes hCAP18, the precursor protein from which LL-37 is cleaved. In simple terms: more vitamin D means more LL-37 production. Less vitamin D means less LL-37 production.

This is one of the primary mechanisms by which vitamin D supports immune function. When researchers identified that vitamin D deficiency correlated with increased infection susceptibility, the LL-37 pathway emerged as a central explanation. Individuals with low vitamin D (<30 ng/mL) produce significantly less endogenous LL-37 than those with optimal levels (40–60 ng/mL).

Practical Implications for LL-37 Users

Vitamin D Optimization Protocol:

Test your vitamin D level — order a 25-hydroxyvitamin D blood test. Optimal range for immune function and LL-37 production: 40–60 ng/mL
Supplement if deficient — vitamin D3 supplementation (2,000–5,000 IU daily for most adults) to achieve and maintain optimal levels; retest after 8–12 weeks
Include vitamin K2 — vitamin K2 (MK-7 form, 100–200 mcg daily) supports proper calcium metabolism when supplementing higher-dose vitamin D
Foundation before exogenous LL-37 — optimize vitamin D before starting exogenous LL-37. This maximizes endogenous production and amplifies the benefit of supplementation
Synergistic effect — exogenous LL-37 + optimized vitamin D = exogenous peptide supplement + maximized endogenous production — the most comprehensive approach to LL-37 levels

Vitamin D is not optional — it is foundational. Exogenous LL-37 supplementation without addressing vitamin D deficiency is like adding a supplement while ignoring the body's primary production pathway. Optimize vitamin D first. Then use exogenous LL-37 to boost levels further if needed. This dual approach provides the most comprehensive immune support.

LL-37 Stacking Protocols

LL-37 stacking follows the principle of complementary mechanisms. LL-37 excels at direct antimicrobial defense and innate immune modulation. The best stacks pair it with peptides that address different aspects of immune function, wound healing, or inflammation — creating multi-pathway coverage that no single peptide provides alone.

LL-37 + Thymosin Alpha-1 — The Comprehensive Immune Stack

The most popular LL-37 stack for immune support. LL-37 provides innate immune defense (direct antimicrobial activity, TLR modulation, neutrophil recruitment), while Thymosin Alpha-1 enhances adaptive immunity (T-cell maturation, dendritic cell function, NK cell activity). Together they cover both arms of the immune system for comprehensive defense.

Compound	Dose	Frequency	Purpose
LL-37	100 mcg SubQ	Once daily	Direct antimicrobial defense, innate immune modulation, TLR signaling
Thymosin Alpha-1	1.6 mg SubQ	2–3x per week	Adaptive immune enhancement, T-cell maturation, NK cell activity

Innate + adaptive immune synergy. LL-37 activates the fast-acting innate immune response (first line of defense), while Thymosin Alpha-1 strengthens the slower but more targeted adaptive immune response (T-cells, antibodies). This combination is the closest thing to comprehensive immune system support available through peptide protocols.

LL-37 + BPC-157 (Wound Healing + Gut Health)

Combines LL-37's antimicrobial defense and wound healing properties with BPC-157's growth factor upregulation and tissue repair capabilities. Particularly effective for gut health (where both peptides are naturally active) and for wound healing protocols where antimicrobial protection and tissue regeneration are both needed.

Compound	Dose	Frequency	Purpose
LL-37	50–100 mcg SubQ	Once daily	Antimicrobial defense, angiogenesis, re-epithelialization, mucosal barrier support
BPC-157	250 mcg SubQ	1–2x daily	Growth factor upregulation, tissue repair, gut healing, angiogenesis

LL-37 + KPV (Antimicrobial + Anti-Inflammatory)

Pairs LL-37's antimicrobial and immunostimulatory properties with KPV's potent anti-inflammatory activity. KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling and reduces pro-inflammatory cytokine production. This stack is particularly useful when both infection and inflammation are present — LL-37 addresses the microbial threat while KPV calms the inflammatory response.

Compound	Dose	Frequency	Purpose
LL-37	100 mcg SubQ	Once daily	Direct antimicrobial activity, innate immune activation, biofilm disruption
KPV	500 mcg SubQ or oral	1–2x daily	NF-kB inhibition, anti-inflammatory cytokine modulation, gut inflammation

LL-37 + TB-500 (Immune Defense + Systemic Tissue Repair)

For situations requiring both immune defense and broad tissue repair. TB-500 (Thymosin Beta-4) promotes cell migration, reduces inflammation, and supports tissue remodeling systemically. Combined with LL-37's antimicrobial and wound healing properties, this stack provides comprehensive support for recovery from infections with tissue damage.

Compound	Dose	Frequency	Purpose
LL-37	100 mcg SubQ	Once daily	Antimicrobial defense, wound healing, immune modulation
TB-500	2.5–5 mg SubQ	2x per week	Systemic tissue repair, cell migration, anti-inflammatory, tissue remodeling

Comprehensive Immune Protocol (Advanced)

For individuals dealing with significant immune challenges who want maximum multi-pathway immune support. This advanced stack covers innate immunity (LL-37), adaptive immunity (Thymosin Alpha-1), gut barrier support (BPC-157), and anti-inflammatory modulation (KPV). Introduce compounds one at a time over 2–3 weeks, not all simultaneously.

Compound	Dose	Frequency	Purpose
LL-37	100 mcg SubQ	Once daily	Innate immunity, antimicrobial, biofilm disruption
Thymosin Alpha-1	1.6 mg SubQ	2–3x per week	Adaptive immunity, T-cell and NK cell support
BPC-157	250 mcg SubQ or oral	1–2x daily	Gut healing, tissue repair, growth factor support
KPV	500 mcg SubQ or oral	1–2x daily	Anti-inflammatory, NF-kB modulation, gut inflammation

Introduce one compound at a time. When building a multi-peptide immune stack, do not start all compounds simultaneously. Add one new peptide every 5–7 days so you can assess individual response and detect adverse reactions. Start with LL-37, then add Thymosin Alpha-1, then BPC-157, then KPV.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: LL-37 is an endogenous peptide — your body naturally produces it. This provides some baseline safety context that purely synthetic peptides lack. However, exogenous administration of LL-37 at supraphysiological doses has not been extensively studied in humans. The primary safety concerns are excessive immune stimulation, potential autoimmune activation in susceptible individuals, and injection site reactions. LL-37 is implicated in the pathology of psoriasis and rosacea when overexpressed endogenously.

Common Side Effects

Dose-dependent and generally manageable:

Injection site reactions — redness, swelling, warmth, or mild pain at the injection site; more common with LL-37 than many other peptides due to local immune activation
Flu-like symptoms — fatigue, mild body aches, low-grade fever; typically occurs during the first few days as the immune system responds, especially at higher doses
Fatigue — may indicate the immune system is actively ramping up; usually resolves within 3–5 days of consistent use
Herxheimer-like reactions — temporary worsening of symptoms when biofilms are disrupted and previously protected bacteria are exposed; more common in chronic infection protocols

Less common:

Skin flushing or localized rash — may indicate mast cell activation at the injection site
Headache — usually transient and resolves with continued use
GI discomfort — more common with oral or higher-dose subcutaneous administration

Injection site reactions are the most common side effect and are directly related to LL-37's immune-activating properties. Rotating injection sites and starting at a lower dose (50 mcg) minimizes this. If injection site reactions are severe or persistent, reduce the dose or increase the interval between injections.

Autoimmune Risk — The Critical Consideration

LL-37 is implicated in the pathology of several autoimmune and inflammatory conditions when overexpressed endogenously. This is the most important safety consideration for exogenous use:

Psoriasis: LL-37 forms complexes with self-DNA released from damaged skin cells. These LL-37/DNA complexes activate plasmacytoid dendritic cells through TLR9, triggering interferon-alpha production and driving the autoimmune inflammatory cascade characteristic of psoriasis. Exogenous LL-37 could theoretically worsen this pathway.
Rosacea: Overprocessing of hCAP18 by the serine protease kallikrein-5 (KLK5) generates excess LL-37 fragments in facial skin, contributing to the inflammation, erythema, and telangiectasia characteristic of rosacea.
Systemic lupus erythematosus (SLE): Similar to psoriasis, LL-37 can complex with self-nucleic acids and activate autoimmune pathways through TLR signaling in susceptible individuals.

Autoimmune conditions are a contraindication for unsupervised use. If you have psoriasis, rosacea, lupus, or any other autoimmune condition, do NOT use exogenous LL-37 without direct medical supervision. The same properties that make LL-37 effective for immune defense can exacerbate autoimmune pathology in susceptible individuals.

Contraindications

Active psoriasis or rosacea — LL-37 is directly implicated in the pathology of both conditions. Exogenous administration may worsen symptoms.
Systemic lupus erythematosus (SLE) — LL-37/self-nucleic acid complexes can drive autoimmune activation through TLR signaling.
Other active autoimmune conditions — the immune-stimulatory properties of LL-37 could theoretically exacerbate any autoimmune condition. Use only under medical supervision.
Pregnancy and breastfeeding — no safety data exists for exogenous LL-37 during pregnancy or nursing. Avoid entirely.
Active cancer — LL-37 has complex and context-dependent effects on tumor biology. Some research shows anti-tumor activity, while other studies suggest LL-37 may promote angiogenesis in certain tumor types. Avoid use with active malignancies without oncologist supervision.
Mast cell activation syndrome (MCAS) — LL-37 can activate mast cells and trigger degranulation. Individuals with MCAS may experience exacerbation of symptoms.

When to Stop or Reduce Dose

Severe or worsening injection site reactions that do not improve with site rotation and dose reduction
New onset or worsening of skin conditions (rash, plaques, redness, flushing) — could indicate autoimmune activation
Persistent flu-like symptoms beyond the first week that do not resolve with continued use
Signs of excessive immune activation (persistent fatigue, joint pain, unexplained inflammation)
Herxheimer reactions that are too severe to manage — reduce dose temporarily, do not stop abruptly
Any symptom that feels unusual or concerning — err on the side of caution

Regulatory Status: LL-37 is not FDA-approved for human use as an exogenous therapeutic. It is classified as a research peptide / research chemical. Although LL-37 is endogenously produced by the human body, the synthetic peptide sold for research purposes has not been evaluated in large-scale human clinical trials. Regulations vary by jurisdiction — verify your local laws before purchasing.

Common LL-37 Dosing Mistakes

Avoid these common errors to get the most out of your LL-37 protocol:

Starting at too high a dose: LL-37 is a potent immune activator. Starting at 200 mcg without assessing tolerance can cause excessive immune stimulation — fatigue, flu-like symptoms, or injection site flares. Always start at 50 mcg daily and titrate upward over several days to your target dose.

Using LL-37 with active autoimmune conditions without medical supervision: LL-37 is implicated in the pathology of psoriasis, rosacea, and other autoimmune conditions when overexpressed. Exogenous LL-37 could theoretically exacerbate these conditions. If you have any autoimmune disorder, consult a physician before use.

Ignoring vitamin D status: Vitamin D is the primary regulator of endogenous LL-37 expression. If your vitamin D is deficient (below 30 ng/mL), your body’s natural LL-37 production is already compromised. Optimizing vitamin D levels (40–60 ng/mL) is a foundational step that amplifies the benefit of exogenous LL-37.

Expecting LL-37 to replace antibiotics for serious infections: While LL-37 has broad-spectrum antimicrobial properties, it is not a substitute for antibiotics in treating diagnosed bacterial infections. LL-37 is best used as a complement to conventional treatment or for immune support — not as a standalone antimicrobial for serious or systemic infections.

Improper storage destroying the peptide: LL-37 is sensitive to degradation. Reconstituted LL-37 must be refrigerated (2–8°C) and used within 2–4 weeks. Lyophilized (unreconstituted) vials should be stored frozen or refrigerated. Exposure to heat, light, or repeated freeze-thaw cycles degrades the peptide and reduces efficacy.

Using only one administration route when the goal requires another: Subcutaneous injection provides systemic immune support but does not optimally target surface-level infections. For wound healing, topical application delivers LL-37 directly to the tissue. For upper respiratory or sinus infections, intranasal administration is more effective than subcutaneous injection. Match the route to the goal.

Running high-dose protocols for too long without cycling: Prolonged high-dose LL-37 use (200 mcg daily for more than 4 weeks) carries a theoretical risk of excessive immune activation and potential autoimmune pathway promotion. Acute protocols should be time-limited (2–4 weeks). Maintenance protocols should use lower doses (50 mcg) with periodic breaks.

Not supporting overall immune function: LL-37 works within the context of a functioning immune system. If foundational factors are neglected — sleep, vitamin D, zinc, vitamin C, gut health — exogenous LL-37 will be less effective. Optimize the basics first, then use LL-37 to augment immune capacity.

Stacking LL-37 with multiple immune stimulators simultaneously without titrating: Combining LL-37 with Thymosin Alpha-1, KPV, and other immune peptides all at once can create unpredictable immune activation. Introduce one compound at a time, assess response over 5–7 days, then add the next. This allows you to identify which compounds are contributing to the response and to detect adverse reactions early.

Frequently Asked Questions

Key Takeaways

LL-37 is the only human cathelicidin antimicrobial peptide— a 37-amino-acid endogenous host defense peptide derived from hCAP18
Standard dose: 50–200 mcg SubQ daily, depending on goal — 50 mcg for maintenance, 100 mcg for standard immune support, 100–200 mcg for acute infections or biofilm disruption
Multiple administration routes: subcutaneous (systemic), topical (wound healing), intranasal (respiratory) — match the route to the goal
Broad-spectrum antimicrobial activity — disrupts bacterial, viral, and fungal membranes through direct physical interaction
Anti-biofilm activity — penetrates and disrupts bacterial biofilm structures, a key area of interest for Lyme disease and chronic infections
Vitamin D is foundational: vitamin D directly upregulates endogenous LL-37 production. Optimize vitamin D (40–60 ng/mL) before or alongside exogenous LL-37 use
Best immune stack: LL-37 + Thymosin Alpha-1 for innate + adaptive immune synergy
Start low, titrate up: Begin at 50 mcg daily for 3–5 days before increasing. LL-37 is a potent immune activator and high starting doses can cause flu-like symptoms
Autoimmune caution: LL-37 is implicated in psoriasis, rosacea, and lupus pathology when overexpressed. Individuals with autoimmune conditions should not use LL-37 without medical supervision
Cycling recommended: 2–4 weeks for acute use; 4–8 weeks for maintenance protocols, then 2–4 weeks off
Not FDA-approved — classified as a research peptide. Strong preclinical evidence but limited human clinical trials for exogenous administration. Check local regulations.

This article is for educational and informational purposes only. See our Disclaimer.

References

Zanetti M. “Cathelicidins, multifunctional peptides of the innate immunity.” J Leukoc Biol. 2004;75(1):39-48. PubMed
Vandamme D, et al. “A comprehensive summary of LL-37, the factotum human cathelicidin peptide.” Cell Immunol. 2012;280(1):22-35. PubMed
Wang TT, et al. “Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression.” J Immunol. 2004;173(5):2909-2912. PubMed
Liu PT, et al. “Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.” Science. 2006;311(5768):1770-1773. PubMed
Bowdish DM, et al. “Immunomodulatory activities of small host defense peptides.” Antimicrob Agents Chemother. 2005;49(5):1727-1732. PubMed
Overhage J, et al. “Human host defense peptide LL-37 prevents bacterial biofilm formation.” Infect Immun. 2008;76(9):4176-4182. PubMed
Lande R, et al. “Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.” Nature. 2007;449(7162):564-569. PubMed
Yamasaki K, et al. “Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.” Nat Med. 2007;13(8):975-980. PubMed
Koczulla R, et al. “An angiogenic role for the human peptide antibiotic LL-37/hCAP-18.” J Clin Invest. 2003;111(11):1665-1672. PubMed
Barlow PG, et al. “Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37.” PLoS One. 2011;6(10):e25333. PubMed

Next Steps

Continue your research with these resources.

Thymosin Alpha-1 Dosage Guide

Learn dosing protocols for Thymosin Alpha-1 — the ideal complement to LL-37 for comprehensive innate + adaptive immune support.

Read Guide

Dosage Calculator

Calculate your exact LL-37 dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory